https://www.selleckchem.com/pr....oducts/cerivastatin-
0, 95% confidence interval 1.0-81.9) was associated with a higher risk of surgery. In patients with Crohn's disease who have failed anti-TNF and either vedolizumab or ustekinumab, at week 48, the surgery rate is 23.5% and the remission rate after a third line biologic therapy is 30.7%. In patients with Crohn's disease who have failed anti-TNF and either vedolizumab or ustekinumab, at week 48, the surgery rate is 23.5% and the remission rate after a third line biologic therapy is 30.7%.Increasing efforts are being made to und
Like
Comment
Share
